| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Hemab Therapeutics Holdings, Inc.$43.32
+0.01 (+0.02%)
D 35Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.21 B
EPS
-
P/E Ratio
-
Value Trade
5.61 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
19.46 M
Operating CF
-21.58 M
Total Assets
175.26 M
Total Liabilities
13.71 M
Equity
-198.62 M
D/E Ratio
12,345
-8.71 %
Week
-16.13 %
1 Month
-16.13 %
3 Month
-16.13 %
6 Month
-16.13 %
5 Year
-16.13 %
All Time
Cash Data
Cash Position
163.53 M
Monthly Burn
7.20 M
Runway
21 mo
Burn Trend
SEC Filing
May 21, 2026
Overview
Volume
307.36 K
52 Week Range
23.00 - 32
% held by Insiders
28.79 %
% held by Institutions
32.9 %
Enterprise Value
1.41 B
Total Shares
39.25 M
Short %
5.16 %
Float Shares
15.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hemab Therapeutics Holdings, Inc.
18Total events
3Upcoming
2Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲Oral PresentationSutacimigPresentation
Subscribe to view catalyst details
TBD
◆Poster PresentationSutacimigPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-14 | Sutacimig (HMB-001) | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-14 | Sutacimig (HMB-001) | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-07-14 | Sutacimig (HMB-001) | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D35
Pipeline Score $245M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 46%
Micro Cap (rank 493 of 912)
Percentile RankHemab Therapeutics Holdings, Inc. faces pipeline headwinds (35/100), with $739M risk-adjusted pipeline value, led by Sutacimig in Congenital Factor VII Deficiency (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sutacimig Small molecule | Congenital Factor VII Deficiency | Phase 2 | NCT07347249 | 60% | $657M | RECRUITING | 18 | AVERAGE | D (29) | Jul 1, 2026 | - | LOW May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sutacimig BreakthroughFast TrackOrphan | Glanzmann thrombasthenia and Factor VII deficiency | Phase 2 | 2026-07-14 | 92% of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig; the mean high intensity annualized treated bleed event rate was reduced by 62% over the treatment and extension period; the mean ATBR was reduced over the treatment and extension period; in the low dose weekly regimen cohort, the mean ATBR was reduced by approximately 84% Read More | Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress Read More | |
sutacimig BreakthroughFast TrackOrphan | Glanzmann thrombasthenia and Factor VII deficiency | Phase 2 | 2026-07-14 | 92% of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig; the mean high intensity annualized treated bleed event rate was reduced by 62% over the treatment and extension period; the mean ATBR was reduced over the treatment and extension period; in the low dose weekly regimen cohort, the mean ATBR was reduced by approximately 84% Read More | Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress Read More | |
sutacimig BreakthroughFast TrackOrphan | Glanzmann thrombasthenia and Factor VII deficiency | Phase 2 | 2026-07-14 | 92% of participants who had bled during the run-in experienced reductions in treated bleed rates on sutacimig; the mean high intensity annualized treated bleed event rate was reduced by 62% over the treatment and extension period; the mean ATBR was reduced over the treatment and extension period; in the low dose weekly regimen cohort, the mean ATBR was reduced by approximately 84% Read More | Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COAG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COAG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COAG▲ +9.6%on this news
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Therapeutics presented promising clinical and preclinical data for sutacimig at the ISTH 2026 Congress, showing significant bleed reduction in patients with Glanzmann thrombasthenia and Factor VII deficiency. The Phase 2 long-term extension data indicated a manageable safety profile and FDA agreement on advancing to Phase 3 trials. Additionally, preclinical findings suggest sutacimig's broad applicability in treating bleeding disorders.
Read more →COAG▲ 0%today
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Hemab Therapeutics presented promising clinical data for HMB-002 in treating Von Willebrand Disease and introduced HMB-003 for heavy menstrual bleeding at the ISTH 2026 Congress. HMB-002 demonstrated significant increases in Von Willebrand Factor and Factor VIII, supporting its potential for monthly dosing. HMB-003 is designed as a non-hormonal antifibrinolytic to address heavy menstrual bleeding, aiming to provide effective treatment options for women.
Read more →COAG▲ +16.8%on this news· ran to +33% by day 1
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
Hemab Therapeutics announced significant advancements in its blood coagulation programs, including promising first-in-human data for HMB-002 in Von Willebrand disease and the introduction of HMB-003, a new peptide plasmin inhibitor. The company plans to present nine studies at the ISTH 2026 Congress, showcasing its commitment to addressing critical gaps in coagulation disorder treatments. Sutacimig has also received FDA Breakthrough Therapy designation, with a Phase 3 trial expected to begin in the second half of 2026.
Read more →COAGHemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, where its management team will present and hold investor meetings. The event is scheduled for June 4, 2026, in New York, NY. Hemab is focused on developing therapies for blood coagulation disorders, including treatments for Glanzmann thrombasthenia and Von Willebrand Disease.
Read more →COAGHemab Therapeutics Reports First Quarter 2026 Financial Results Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for s
Hemab Therapeutics has reported its first quarter financial results for 2026, highlighting the successful completion of an initial public offering that raised $346.7 million and secured a listing on Nasdaq. The company received Breakthrough Therapy Designation for sutacimig, a bispecific antibody for Glanzmann thrombasthenia. Despite these advancements, Hemab reported a net loss of $22.687 million in the quarter, with a decrease in cash reserves compared to the previous quarter.
Read more →COAGHemab Therapeutics Announces Pricing of Upsized Initial Public Offering
Hemab Therapeutics Holdings, Inc. has announced the pricing of its initial public offering, offering 16,750,000 shares at $18.00 each. The IPO is expected to generate around $301.5 million in gross proceeds. Trading is set to begin on the Nasdaq Global Select Market under the ticker 'COAG' on May 1, 2026, with the offering closing around May 4, 2026.
Read more →Competitive Position
How COAG ranks across every disease it competes inCompetitive Position is a premium feature
See how COAG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial